Search results
Showing 271 to 285 of 1401 results for 0
Evidence-based recommendations on photodynamic therapy for brain tumours. This involves giving the patient a drug that makes the tissue sensitive to light and then activating it with a laser light source to destroy the tumour cells.
View recommendations for HTG184Show all sections
Sections for HTG184
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)
Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.
Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management (NG231)
This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques. It aims to improve outcomes by ensuring the most effective investigations and treatments are used.
icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)
NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .
Evidence-based recommendations on insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section. The catheter aims to help induction by causing dilation of the cervix when the cervix is unfavourable for induction. The double balloon squeezes the cervix and stimulates local prostaglandin release, which leads to cervical ripening.
Extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome (HTG248)
Evidence-based recommendations on extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome. This involves using a machine to deliver sound waves to the painful area to stimulate healing.
View recommendations for HTG248Show all sections
Sections for HTG248
Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) (HTG29)
Evidence-based recommendations on complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique). This involves complete surgical tumour removal with intraoperative heated chemotherapy, and is followed by postoperative intraperitoneal chemotherapy.
View recommendations for HTG29Show all sections
Sections for HTG29
Our resource planner tool to help you plan for and implement NICE guidance.
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.
Sacral nerve stimulation for urge incontinence and urgency-frequency (HTG37)
Evidence-based recommendations on sacral nerve stimulation for urge incontinence and urgency-frequency. This involves placing electrodes and connecting them to an implantable pulse generator.
View recommendations for HTG37Show all sections
Sections for HTG37